Season 2 of MedCity Pivot Podcast Launches with Conversation of Zephyr AI CTO
Season 2 of our MedCity Pivot Podcast launches today with a conversation about how AI can be leveraged to transform precision medicine.
Merck’s $11B Prometheus Acquisition Brings IBD Drug & Precision Medicine Platform
Merck is acquiring Prometheus Biosciences and a lead drug candidate in development for inflammatory bowel disorders. The deal comes as Merck looks for drug prospects that could make up for revenue declines facing blockbuster seller Keytruda, which faces patent expirations in coming years.
Beyond Analytics: How Sellers Dorsey is Hard-Coding Value into Medicaid Policy [Video]
How to turn analytics into actual policy outcomes.
Improving Value-based Care with Optimized Drug Therapy
Optimizing drug routines allows prescribers to make more informed decisions that reduce risk and improve quality of care. The result is better outcomes for both patients and organizations.
Nest Genomics Raises $8.5M to Increase Access to Patients’ Genetic Information
Nest Genomics just closed a $8.5 million seed financing round. The company provides the software infrastructure needed for health systems, clinics, drugmakers and payers to launch and scale genomic programs. It also provides tools for patients to easily access their genetic information.
2 Changes Siddhartha Mukherjee Is Calling for in Cancer Care
If the medical field wants to make serious progress on the Cancer Moonshot effort, it must expand its definition of personalized medicine and explore fresh approaches to cancer prevention, according to Dr. Siddhartha Mukherjee, a Pulitzer Prize-winning author and cancer physician at Columbia University Medical Center.
Where GE Healthcare stands 2 months away from spinning out
GE Healthcare is preparing for its spinoff from GE, which is planned for the first week of January. The company’s split will allow it to operate under a new board, as well as manage its own capital. That capital will be primarily invested in acquisitions and research and development efforts, according to GE Healthcare's CEO for the U.S. and Canada.
The Power Behind Enterprise EHR Software for Large Healthcare Systems
Enterprise EHR boosts scalability, interoperability, and governance for large healthcare systems.
Reimagining healthcare in a quantum era
With promises of more efficient and reliable diagnoses, future breakthroughs in personalized medicine and targeted therapeutics, and an expedited R&D lifecycle, industry leaders must be prepared to invest in quantum technologies to deliver better outcomes for their organizations and patients.
A look ahead: How medical affairs may evolve over the next five years
Covid changed things for medical affairs teams at pharmaceutical companies, causing was a fundamental shift in the way they worked and functioned. The role of the medical science liaison—a key member of the medical affairs team—has also evolved.
Meditech’s genomic solution, which provides a patient’s full genetic history in their EHR, is now live
Clinton, Missouri-based Golden Valley Memorial Healthcare is the first to deploy Meditech's solution, Expanse Genomics. It allows providers to analyze and parse genetic results into actionable data that is displayed directly in patient charts, according to Meditech.
StartUPDATES: New developments from healthcare startups
Check out new developments from Healthmine, Light Solutions Company, Zephyr AI, and more.
presented by
Survey on the Healthcare Financial Landscape Offers a Roadmap for Stakeholders
Zelis highlights how employers, payers, and consumers are integrating digital tools to manage healthcare costs.
Precision oncology startup AnHeart Therapeutics co-founder shares cancer drug strategy
AnHeart Therapeutics is developing a pipeline of precision oncology therapeutics. Chief Business Officer and Co-founder Lihua Zheng provided an overview of company's strategy in response to emailed questions.
Precision medicine: A new dimension to improve care outcomes
All the hype around precision medicine can make it seem intimidating and foreign. The good news is that it does not represent a departure from current clinical practice, and it can significantly improve patient care.
Sema4 secures a deal to acquire GeneDx, capturing $200M in private investment
The transaction also brought a $200 million investment for Sema4 from life science investors including Pfizer, which can help the combined company's goal of translating insights from genomics data and analytics into making precision medicine a standard of care.
In an age of precision medicine, decentralized clinical trials are a valuable tool
ntegrated software, accessible genetic data, and advances in precision medicine can transform the lives of millions of patients–if the clinical trial and larger medical industry embrace these trends.
Accelerating the adoption of precision medicine through collaborative efforts across the healthcare industry
While much progress has been made, many patients have molecular drivers of disease that are not detected, interpreted and acted upon with precision therapies, leaving potential life-changing treatments on the table.